These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10504719)

  • 1. Blocking HIV entry.
    Buzko OV; Shokat KM
    Nat Struct Biol; 1999 Oct; 6(10):906-8. PubMed ID: 10504719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
    Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
    Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.
    Otaka A; Nakamura M; Nameki D; Kodama E; Uchiyama S; Nakamura S; Nakano H; Tamamura H; Kobayashi Y; Matsuoka M; Fujii N
    Angew Chem Int Ed Engl; 2002 Aug; 41(16):2937-40. PubMed ID: 12203417
    [No Abstract]   [Full Text] [Related]  

  • 4. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
    Kazmierski WM; Kenakin TP; Gudmundsson KS
    Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
    Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
    ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
    [No Abstract]   [Full Text] [Related]  

  • 7. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
    Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
    Barbouche R; Decroly E; Kieny MP; Fenouillet E
    Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein design of an HIV-1 entry inhibitor.
    Root MJ; Kay MS; Kim PS
    Science; 2001 Feb; 291(5505):884-8. PubMed ID: 11229405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
    Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G
    Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of HIV-1 fusion inhibitors targeting gp41.
    Lu K; Asyifah MR; Shao F; Zhang D
    Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
    Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
    Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 15. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
    Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
    Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunology. Close to the edge: neutralizing the HIV-1 envelope.
    Nabel GJ
    Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Picture story. Keeping HIV out.
    Konforti B
    Nat Struct Biol; 1999 Nov; 6(11):1004. PubMed ID: 10542088
    [No Abstract]   [Full Text] [Related]  

  • 19. HIV genetic mutations causing resistance to the new drug T-20: recent findings.
    Bean P
    Am Clin Lab; 2002 Oct; 21(8):15-6. PubMed ID: 12440170
    [No Abstract]   [Full Text] [Related]  

  • 20. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
    J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.